Overseas-Registered Products Available for Cyclophosphamide and Ifosfamide Injection Shortages
Summary
Baxter Healthcare has notified TGA Australia that global supply constraints due to manufacturing issues are affecting Endoxan (cyclophosphamide) 2g and Holoxan (ifosfamide) 2g powder for injection vials. These medicines are used to treat various types of cancer, diseases of the immune system, and to prevent rejection of organ transplants. The shortages are expected to continue until the end of June 2026. TGA has approved the supply of multiple overseas-registered cyclophosphamide and ifosfamide injection products under section 19A of the Therapeutic Goods Act 1989 to reduce the impact of these shortages.
About this source
GovPing monitors TGA Australia Safety Alerts for new consumer protection regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 1 changes logged to date.
What changed
Baxter Healthcare has notified TGA Australia of global supply constraints affecting cyclophosphamide (Endoxan) 2g and ifosfamide (Holoxan) 2g powder for injection vials due to manufacturing issues. The shortages are expected to persist until the end of June 2026. TGA has exercised its powers under section 19A of the Therapeutic Goods Act 1989 to approve the supply of multiple overseas-registered alternative products in various strengths to mitigate the shortage impact.
Healthcare providers treating patients who rely on these chemotherapy agents and immune system treatments should consult the Section 19A approvals database and Medicine shortage reports database to identify approved alternatives and sourcing options. Pharmacies and hospitals should review current stock and sourcing procedures to ensure continuity of care for cancer patients and transplant recipients during this shortage period.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Overseas-registered products available for cyclophosphamide and ifosfamide injection shortages
Published
22 April 2026
- Listen
Share
Endoxan (cyclophosphamide) 2 g (as monohydrate) powder for injection vial
Holoxan (ifosfamide) 2 g powder for injection vial.
These medicines are used to treat various types of cancer. Cyclophosphamide is also used to treat some diseases of the immune system, and to prevent rejection of organ transplants.
The shortages are expected to continue until the end of June 2026.
We have approved the supply of multiple overseas-registered cyclophosphamide and ifosfamide injection products in various strengths under section 19A of the Therapeutic Goods Act 1989 to reduce the impact of these shortages.
Go to About the cyclophosphamide and ifosfamide injection shortages for more information about the shortages, including details of the overseas-registered products and how to obtain them.
The Section 19A approvals database and the Medicine shortage reports database also provide up-to-date information about these products and the shortages (search by the active ingredient).
Topics
- Shortages and supply disruptions
Featured in
- Prescription medicines collection
Product types
- Prescription medicines
Parties
Related changes
Get daily alerts for TGA Australia Safety Alerts
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from TGA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when TGA Australia Safety Alerts publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.